Proactive Investors - Run By Investors For Investors

Imugene presenting all three immuno-oncology programs at AACR Annual Meeting

Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive Investors about news the company's KEY-Vaxx and B-Vaxx cancer vaccine programs will be presented at the American Association for Cancer Research (AACR) 2019 Annual Meeting.

Lead candidate HER-Vaxx was tapped for inclusion last week, meaning that now all three of the clinical stage immuno-oncology company's programs will be featured.

Meet White Rock Minerals Ltd and Meteoric Resources NL at our event, Melbourne , 27 August 2019. Register here »
View full IMU profile View Profile

Imugene Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use